Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antiandrogens

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Antiandrogens. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-003705-27 Sponsor Protocol Number: MK URO 4 Start Date*: 2007-09-27
    Sponsor Name:AKH Vienna
    Full Title: RANDOMIZED, CONTROLLED BIOMARKER STUDY EVALUATING THE ANTI-ANGIOGENIC ACTIVITY OF SUNITINIB IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS TREATED BY DOCETAXEL
    Medical condition: hormone refraktory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002205-31 Sponsor Protocol Number: CA180-085 Start Date*: 2006-12-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0 dated 15-Aug-06)
    Medical condition: Advanced prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003087-59 Sponsor Protocol Number: EFC6193 Start Date*: 2006-11-29
    Sponsor Name:sanofi aventis recherche et developpement
    Full Title: A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone ...
    Medical condition: Hormone Refractory Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) BE (Completed) NL (Completed) SK (Completed) DK (Completed) SE (Completed) FI (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002730-30 Sponsor Protocol Number: IB 2008-23 Start Date*: 2008-08-04
    Sponsor Name:Institut Bergonié - Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-ouest
    Full Title: A PHASE II TRIAL TO ASSESS THE EFFICACY OF EFAVIRENZ IN METASTATIC PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE CANCER
    Medical condition: Male patients aged 18 and over with castration-refractory metastatic prostate cancer histologically confirmed with WHO performance status ranged from 0 to 2, and without any clinical symptom relate...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036947 Prostatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018370-21 Sponsor Protocol Number: C-II-007 Start Date*: 2010-05-27
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research EWIV
    Full Title: Phase I/II study with Temsirolimus versus no add-on in patients with castration resistant prostate cancer (CRPC) receiving first-line Docetaxel chemotherapy CESAR Study in Prostrate Cancer wi...
    Medical condition: castration resistant prostate cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005967-27 Sponsor Protocol Number: ASL605LIOM03 PROMET Start Date*: 2006-10-31
    Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE
    Full Title: Study pilot of metronomic chemotherapy with ciclofosfamide, celecoxib and desametasone in patients with diagnosis of carcinoma of the refractory ormon prostate in advanced stage appraisal pharmac...
    Medical condition: ORMONO REFRACTORY CARCINOMA OF PROSTATE IN ADVANCED STAGE
    Disease: Version SOC Term Classification Code Term Level
    6.1 10007280 PT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004984-11 Sponsor Protocol Number: P150962J Start Date*: 2018-07-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: "Study of maintenance of the efficacy and adverse effects of pharmacological treatments in sex offenders with paraphilia" ESPARA
    Medical condition: Sexual offenders with paraphilia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10033888 Paraphilia PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021962-31 Sponsor Protocol Number: Protocolversion1-20100713 Start Date*: 2011-10-06
    Sponsor Name:Bo Lennernäs
    Full Title: KEES- A single arm phase II trial of the peroral regimen KEES (Ketokonazole, Etoposide, Estramustine, Sendoxan) in patients with Castration Resistant Prostate Cancer (CRPC)
    Medical condition: Men with castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001891-35 Sponsor Protocol Number: D4200C00080 Start Date*: 2007-06-22
    Sponsor Name:AstraZeneca SAS
    Full Title: A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metasta...
    Medical condition: Metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000931-15 Sponsor Protocol Number: ICR-CTSU/2016/10060 Start Date*: 2018-07-02
    Sponsor Name:Institute of Cancer Research
    Full Title: PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer.
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-000601-49 Sponsor Protocol Number: ICR-CTSU/2011/10030 Start Date*: 2012-03-14
    Sponsor Name:The Institute of Cancer Research [...]
    1. The Institute of Cancer Research
    2. Royal Marsden NHS Foundation Trust
    Full Title: TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer.
    Medical condition: Advanced Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-005504-34 Sponsor Protocol Number: C-II-010 Start Date*: 2014-07-11
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research - EWIV
    Full Title: Randomized phase II CAbazitaxel dose Individualization and Neutropenia prevention TriAl (CAINTA)
    Medical condition: Stage II with advanced Castration-Resistant Prostate Cancer (CRPC)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003733-23 Sponsor Protocol Number: CB-03-01/34 Start Date*: 2017-05-09
    Sponsor Name:Cassiopea S.p.A.
    Full Title: A PHASE 2, MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CB 03 01 (CORTEXOLONE 17α-PROPIONATE) SOLUTION FOR THE...
    Medical condition: AGA (androgenic alopecia) is scalp hair loss that occurs due to an underlying susceptibility of hair follicles to androgenic miniaturization. In the hair follicle, testosterone is converted by 5α-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10068558 Androgenic alopecia LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002735-16 Sponsor Protocol Number: ABI-STAR-2016 Start Date*: 2016-12-13
    Sponsor Name:Otto-von-Guericke-Universität Magdeburg
    Full Title: Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®)
    Medical condition: metastatic castration-resistant prostate carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022802-41 Sponsor Protocol Number: 3104001 Start Date*: 2011-02-25
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-201 IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER: OPEN, NON-RANDOMISED, UNCONTROLLED, MULTICENTRE, MULTIPLE DOSE ESCALATION STUDY WITH A RANDOMISED PHASE I...
    Medical condition: Progressive castration resistant prostate cancer (MedDRA: hormone-refractory prostate cancer)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) FI (Completed) CZ (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004485-21 Sponsor Protocol Number: HE9A/14 Start Date*: 2015-04-03
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: A study of cabazitaxel treatment in castration resistant bone metastatic prostate cancer patients evaluating the tumor microenvironment
    Medical condition: Castration resistant bone metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001392-22 Sponsor Protocol Number: RC16_0467 Start Date*: 2017-09-27
    Sponsor Name:CHU de Nantes
    Full Title: Randomized double-blind study on the benefit of spironolactone for treating acne of adult woman
    Medical condition: Acne vulgaris of adult woman
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005036-28 Sponsor Protocol Number: 2012/41 Start Date*: 2013-04-12
    Sponsor Name:CENTRE ANTOINE LACASSAGNE
    Full Title: Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetate
    Medical condition: Prostate cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002094-23 Sponsor Protocol Number: EORTC 30021 Start Date*: 2004-12-20
    Sponsor Name:EORTC
    Full Title: Randomized phase II trial of Docetaxel (Taxotere) and Oblimersen vs Taxotere alone in patients with HRPC
    Medical condition: Patients with Hormone- Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001186 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001961-33 Sponsor Protocol Number: CFG920X2101 Start Date*: 2013-01-29
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer
    Medical condition: Metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Temporarily Halted) BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 06:55:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA